YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

The Company is currently advancing two late-stage products:

• Nimotuzumab: EGFR-targeting Affinity-Optimized Antibody™ in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation; approved for marketing in 23 countries.

• AeroLEF®: proprietary, inhaled-delivery composition of fentanyl in development for the treatment of moderate to severe acute pain.

For more information, visit: http://www.ymbiosciences.com/

Login or register to write a review